Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 14/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 11/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 11/20 | 0.59 |
| ▸ | F10 | P00742 | 1/20 | 0.55 |
| ▸ | PLAT | P00750 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3248071 | 0.94 | F2 (0.65) | F2PRSS1PRSS2PRSS3F10 | |
| Trifluoroacetic Acid SCHEMBL6424420 | 0.93 | F2 (0.59) | F2PRSS1PRSS2PRSS3F10 | |
| Trifluoroacetic Acid SCHEMBL3242113 | 0.91 | F2 (0.63) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL3241668 | 0.89 | F2 (0.61) | F2PRSS1PRSS2PRSS3F10 | |
| Trifluoroacetic Acid SCHEMBL3242104 | 0.88 | F2 (0.60) | F2PRSS1PRSS2PRSS3F10 | |
| Hydrochloric Acid SCHEMBL3244021 | 0.88 | F2 (0.60) | F2PRSS1PRSS2PRSS3F10 | |
| SCHEMBL3247627 | 0.88 | F2 (0.64) | F2PRSS1PRSS2PRSS3F10 | |
| Trifluoroacetic Acid SCHEMBL3245569 | 0.88 | F2 (0.56) | F2PRSS1PRSS2PRSS3F10 | |
| Trifluoroacetic Acid SCHEMBL3268440 | 0.87 | F2 (0.64) | F2PRSS1PRSS2PRSS3F10 | |
| Trifluoroacetic Acid SCHEMBL3242074 | 0.87 | F2 (0.72) | F2PRSS1PRSS2PRSS3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1589029-A2 | Pyrazinone protease inhibitors | Johnson & Johnson Pharmaceutical Research & Development L.L.C. (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1086122-B1 | PYRAZINONE PROTEASE INHIBITORS | JOHNSON & JOHNSON PHARM RES (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6514978-B2 | Compounds such as 1-(n-(2-(amidinoaminooxy)ethyl)amino) carbonylmethyl-6-methyl-3-(phenethylamino)-pyrazinone attached to a polymer coated onto a medical device for blood collection or storage; antiagglomerants | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| US-20010021713-A1 | Thromboresistant materials incorporating pyrazinone protease inhibitors | LU TIANBAO (US) | 2001-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021713-A1 | Thromboresistant materials incorporating pyrazinone protease inhibitors | HPN, SERPINE1, SERPINC1 | F2 23/4885PRSS1 10/4885PRSS2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.